Abbott (NYSE:ABT) today touted short- and long-term data published in the journal Pain, which demonstrated that its dorsal root ganglion stimulation therapy benefits patients suffering from complex regional pain syndrome more than traditional spinal cord stimulation. The Abbott Park, Ill.-based company said it’s the only company in the world approved to offer DRG stimulation. The newly-published data […]
Abbott
Abbott launches St. Jude Medical’s Ensite Precision cardiac mapping
Abbott (NYSE:ABT) yesterday said it launched the EnSite Precision cardiac mapping system it acquired when it paid $25 billion for St. Jude Medical earlier this month. The commercial launch also included the sensor-enabled Advisor FL circular mapping catheter, Abbott said. The system, which won 510(k) clearance from the FDA in December 2016, was used for […]
Dexcom surges on Medicare nod for continuous glucose monitors
DexCom (NSDQ:DXCM) said yesterday that the Centers for Medicare & Medicaid classified therapeutic continuous glucose monitors as durable medical equipment under Medicare Part B. The company’s Dexcom G5 Mobile is the only CGM system that falls under this classification, according to San Diego, Calif.-based DexCom, since patients can make treatment decisions using the device. DXCM […]
St Jude releases FDA-cleared Merlin@home cybersecurity update
Updated with comment from Muddy Waters. Abbott (NYSE:ABT) subsidiary St. Jude Medical said today it launched a cybersecurity update for its Merlin@home remote monitoring system designed for use with implantable pacemakers and defibrillator devices. The Little Canada, Minn.-based company said the move was made to “complement the company’s existing measures and further reduce the extremely low […]
Abbott closes $25B St. Jude buy
Abbott (NYSE:ABT) said today it closed its $25 billion buy of St. Jude Medical (NYSE:STJ), permanently tying up the 2 major medtech players. Under the merger agreement, St. Jude Medical will now be a wholly-owned subsidiary of Abbott, with its last day of trading on the NYSE ending today. “Abbott has a strong track record of successfully integrating […]
Appeals court upholds Patent Office’s invalidity ruling on J&J stents patent
A federal appeals court yesterday upheld a patent board decision invalidating portions of a Johnson & Johnson (NYSE:JNJ) patent covering drug-eluting stents in a case that dates back to 2009. Wyeth, now part of Pfizer (NYSE:PFE), and onetime J&J subsidiary Cordis (which became a part of Cardinal Health in October 2015), sued Abbott (NYSE:ABT) and Boston Scientific (NYSE:BSX), alleging […]
Abbott to close $25B St. Jude buy
Abbott (NYSE:ABT) said today that it plans to close its $25 billion buy of St. Jude Medical (NYSE:STJ) next Wednesday, Jan. 4, after receiving all necessary regulatory clearances for the deal. Abbott touted the acquisition, saying it would position the combined entity to cover “nearly every area” of the cardiovascular market, holding onto the number 1 or 2 […]
Abbott’s $25B St. Jude Medical tie-up approved in China
Anti-trust regulators in China today granted conditional approval to the $25 billion tie-up of Abbott (NYSE:ABT) and St. Jude Medical (NYSE:STJ). China’s Ministry of Commerce said the approval is conditioned on the sale of St. Jude’s small vessel closure device business; the companies would have 20 days from the close of their deal to execute the sale of […]
Alere sues CMS to reinstate its Arriva diabetes unit
Alere (NYSE:ALR) yesterday said that it’s suing to force the Centers for Medicare & Medicaid Services to reinstate its Arriva diabetes division’s enrollment, after the government health insurer yanked the accreditation last month over issues with an excess of claims submissions for deceased patients. Arriva, which develops durable medical equipment for diabetic testing, was informed Oct. 12 that […]
Abbott wins US antitrust approval for $25B St. Jude buy
The US Federal Trade Commission today granted approval to Abbott (NYSE:ABT) to complete its proposed $25 billion acquisition of St. Jude Medical (NYSE:STJ). The approval came with a caveat that the companies divest themselves of 2 cardiovascular medical device businesses – vascular closure devices and “steerable” sheaths. The hurdle shouldn’t be too difficult for the companies, who […]
Report: US regulators poised to clear Abbott’s $25B St. Jude buy
Regulators in the U.S. are positioned to approve Abbott‘s (NYSE:ABT) $25 billion acquisition of St. Jude Medical (NYSE:STJ), according to 2 Reuters sources. The approval from the U.S. Federal Trade Commission could come through as early as this week or the next, according to the Reuters report. The companies were unsure of the conditions necessary for […]